Richard Kones

Richard Kones Richard Kones
Director, Cardio-metabolic Research Institute Houston, Texas, USA


Richard Kones MD, PhD, FAHA, FESC, FRSM, FRSH, FAGS, attended NYU School of Medicine, completed training in New York, continued a NIH Fellowship in cardiology at Tulane University School of Medicine, and worked at the Charity Hospital and Veterans Administration Hospital in New Orleans. He began research on the prevention of loss of heart muscle, atherosclerosis, and chronic diseases. Recent research has focused on PCI and CABG in multivessel disease, prevention of chronic cardiometabolic diseases and related evidence-based interventions to improve clinical outcomes. During the course of his academic career he has had several teaching appointments, received scholarships, awards, and grants. His work includes 115 publications in peer-reviewed medical journals, 6 books, numerous presentations, courses, and lectures; he has peer-reviewed for 150 different medical/health publishers and entities, generally repeatedly for each. As a Fellow/member in leading medical societies and organizations, he has served on a number of committees, and volunteers to support promotion of ideal cardiovascular health at both individual and community levels. As a clinician, researcher, educator/mentor, editor, and public health advocate, Dr. Kones? biography has appeared in a number of editions of Who?s Who and other biographical registries. In the last 6 years he has been invited to lecture, panel, or chair 93 academic events. Further details are available at,, and PubMed

Research Interest

Atherosclerosis/atherothrombosis Acute coronary syndrome-role of inflammation, pathogenesis, outcomes Use of PCI versus CABG in multivessel coronary disease Chronic diseases, mechanisms and mortality Cardiovascular risk: assessment, burden, treatment, mortality Coronary heart disease Clinical decision-making Diets (with respect to cardiometabolic disease), Public health policies Epidemiology (with respect to cardiometabolic disease) Hypertension and Prehypertension Obesity Metabolic syndrome Myocardial energetics/mitochondria Diabetes and Prediabetes Hypercholesterolemia Cholesterol-related atherogenic particles Dyslipidemia (including hypercholesterolemia and hypertriglyceridemia) Physical inactivity Inflammation/C-reactive protein/molecular and oxidative mechanisms Biomarkers Insulin resistance Lifestyle medicine, Public health policies Cardiovascular disease in women, minorities, culture, socially deprived and special populations Primordial, primary, and secondary prevention